Skip to content

Menu

About CLTI
Technology
- Products
Clinical Evidence
U.S. Clinical Trial
Company
- Management
- Clinical Advisors
- News
- Media
- Articles
Contact
International

November 15 2016

LimFlow Receives CE Mark for Purely Percutaneous Critical Limb Ischemia (CLI) Technology Designed to Restore Perfusion for “No Option” Patients

View the article.

LimFlow Announces Presentation of the LimFlow Procedure at a Dedicated Symposium During the Leipzig Interventional Course, LINC 2015 – January 27-30, 2015 LimFlow Receives FDA Approval for U.S. Feasibility Study of Minimally-Invasive Technology Designed to Restore Perfusion in “No Option” Critical Limb Ischemia Patients

Related Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING

US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT

LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

Recent Posts

LIMFLOW RAISES $40 MILLION (€36 MILLION) IN SERIES D FINANCING
US PIVOTAL STUDY AND CLARITI COMPLETE ENROLLMENT
LATE-BREAKING DATA FROM PROMISE I STUDY ON LIMFLOW SYSTEM CONFIRM EXCELLENT SUSTAINED OUTCOMES IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA
THE LIMFLOW SYSTEM FOUND TO BE COST-EFFECTIVE, ACCORDING TO THE NEWEST STUDY PUBLISHED IN THE JOURNAL OF CRITICAL LIMB ISCHEMIA
PUBLICATION OF ONE YEAR OUTCOMES FROM PROMISE I U.S. STUDY OF THE LIMFLOW SYSTEM DEMONSTRATES EXCELLENT SUSTAINED AMPUTATION-FREE SURVIVAL AND WOUND HEALING IN PATIENTS WITH NO-OPTION CHRONIC LIMB-THREATENING ISCHEMIA

LimFlow, Inc.
3031 Tisch Way
110 Plaza West
San Jose, CA 95128
United States of America

info@limflow.com
+1 (888) 478-7705
+1 (408) 898-1459

CAUTION: Investigational device. Limited by Federal law to investigational use.

©2022 LimFlow SA | Site designed by The Deciding Factor, Inc.